In recent years, notable strides have been made in treating feline infectious peritonitis (FIP), particularly in 2024, with GS-441524 becoming available in the US and Wedgewood becoming the first US ...

The antiviral drug molnupiravir (Lagevrio) slashed the risk of death from COVID-19 in half when given early to older adults. It also lowered all-cause deaths among older adults in the Czech Republic ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The antiviral reduced the risk for severe symptoms of ...

In a recent study published in The Lancet Microbe, researchers investigated the effects of molnupiravir on the evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in ...

A new study suggests that the antiviral Molnupiravir may “paradoxically” be driving COVID-19 mutations, creating variants of concern. What is going on? It is all about molnupiravir’s mode of action ...

(The Hill) – A new study published Monday links COVID-19 antiviral created by Merck and new mutations of the virus that have been sequenced around the world. Molnupiravir, known commercially as ...

As coronavirus concerns increase with the changing of the seasons, the most commonly used oral antiviral treatments are in the spotlight once again. Lagevrio acts by introducing mutations, destroying ...

There are currently two approved COVID-19 treatments that can be taken orally: nirmatrelvir-ritonavir (known as Paxlovid and developed by Pfizer) and Merck’s molnupiravir. They have both been shown to ...

A drug used to treat covid-19 appears to be driving the evolution of the SARS-CoV-2 coronavirus, according to an analysis of the 15 million viruses sequenced around the world so far. The analysis ...

Georgia State University. "Molnupiravir administered at human effect size-equivalent dose blocks SARS-CoV-2 transmission in ferrets, researchers find." ScienceDaily. ScienceDaily, 14 August 2023. <www ...

RAHWAY, N.J. & MIAMI--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that the Committee for Medicinal Products ...